Recent Updates
Recently added Catalysts
ARGX

argenx announces size of initial public offering in the United States increased to 5 million ADSs

Key Takeaway: argenx announces size of initial public offering in the United States increased to 5 million ADSs

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis

Full Press Release Details

argenx announces size of initial public offering in the United States increased to 5 million ADSs.
Last updated: May 15, 2017